Alterations in the gut microbiome and metabolism with coronary artery disease severity.
Liu H, Chen X, Hu X, Niu H, Tian R, Wang H, Pang H, Jiang L, Qiu B, Chen X, Zhang Y, Ma Y, Tang S, Li H, Feng S, Zhang S, Zhang C. · 2019
Read Alterations in the gut microbiome and metabolism with coronary artery disease severity. by Liu H, Chen X, Hu X, Niu H, Tian R, Wang H, Pang H, Jiang L, Qiu B, Chen X, Zhang Y, Ma Y, Tang S, Li H, Feng S, Zhang S, Zhang C. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6486680.txt.
Introduction
Liu and co-authors profile gut microbes and blood metabolites across the stages of coronary artery disease, reading bacterial genes and running chemical screens in 161 patients and 40 healthy controls. The mix shifted step by step from health through stable disease to acute coronary syndrome, ruling out a simple sick-versus-well split.
Twenty-nine metabolite modules tracked disease traits, and a bacterial group anchored by Roseburia, Klebsiella, and Ruminococcaceae changed by stage, steering how the body handles taurine, sphingolipids, and ceramides. A classifier built from these measures separated patients from controls with an area under the curve up to 0.955. It could even tell stable disease from acute syndrome.
Catalog record
| CREATOR | Liu H, Chen X, Hu X, Niu H, Tian R, Wang H, Pang H, Jiang L, Qiu B, Chen X, Zhang Y, Ma Y, Tang S, Li H, Feng S, Zhang S, Zhang C. |
|---|---|
| YEAR | 2019 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 62 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Alterations in the gut microbiome and metabolism with coronary artery disease severity By Honghong Liu, Xi Chen, Xiaomin Hu, Haitao Niu, Ran Tian, Hui Wang, Haiyu Pang, Lingjuan Jiang, Bintao Qiu, Xiuting Chen, Yang Zhang, Yiyangzi Ma Published in: Microbiome DOI: 10.1186/s40168-019-0683-9 ABSTRACT Background Coronary artery disease (CAD) is associated with gut microbiota alterations in different populations. Gut microbe-derived metabolites have been proposed as markers of major adverse cardiac events. However, the relationship between the gut microbiome and the different stages of CAD pathophysiology remains to be established by a systematic study. Results Based on multi-omic analyses (sequencing of the V3-V4 regions of the 16S rRNA gene and metabolomics) of 161 CAD patients and 40 healthy controls, we found that the composition of both the gut microbiota and metabolites changed significantly with CAD severity. We identified 29 metabolite modules that were separately classified as being positively or negatively correlated with CAD phenotypes, and the bacterial co-abundance group (CAG) with characteristic changes at different stages of CAD was represented by Roseburia, Klebsiella, Clostridium IV and Ruminococcaceae. The result revealed that certain bacteria might affect atherosclerosis by modulating the metabolic pathways of the host, such as taurine, sphingolipid and ceramide, and benzene metabolism. Moreover, a disease classifier based on differential levels of microbes and metabolites was constructed to discriminate cases from controls and was even able to distinguish stable coronary artery disease from acute coronary syndrome accurately. Conclusion Overall, the composition and functions of the gut microbial community differed from healthy controls to diverse coronary artery disease subtypes. Our study identified the relationships between the features of the gut microbiota and circulating metabolites, providing a new direction for future studies aiming to understand the host–gut microbiota interplay in atherosclerotic pathogenesis. Electronic supplementary material The online version of this article (10.1186/s40168-019-0683-9) contains supplementary material, which is available to authorized users. BACKGROUND Despite the widespread use of medical therapy in the last decade, cardiovascular diseases (CVDs) remain the leading causes of mortality and morbidity in many developed and developing countries, CVDs remain responsible for 17.7 million deaths every year (constituting 31% of all global deaths), and this number corresponds to one of every three deaths in the US and one of every four deaths in Europe [1]. Coronary artery disease (CAD) refers to the myocardial dysfunction and/or organic lesions caused by coronary artery stenosis and insufficient blood supply. Based on clinical symptoms, the extent of arterial blockage and the degree of myocardial injury, CAD is divided into different categories: stable coronary artery disease (SCAD), unstable angina (UA) and myocardial infarction (MI) [2]. SCAD refers to the syndrome of angina pectoris including recurrent, transient episodes of chest pain reflecting demand-supply mismatch [3]. Patients with spontaneous attacks of prolonged angina-type chest discomfort occurring at rest that are associated with vulnerable plaques are categorized as patients with UA [4]. MI is usually accompanied by severe and persistent chest pain, typical ECG changes, and elevated serum biomarkers of myocardial necrosis like cardiac troponins [5]. UA and MI are also referred to as acute coronary syndrome (ACS) (detailed diagnostic criteria are summarized in Additional file 3). The progression of atherosclerotic plaque is considered to be dynamic and complicated, and the detailed mechanisms underlying the formation, development and dislodgement of plaque are largely unknown. Identifying biomarkers of the risk of plaque destabilization and rupture in patients is important for preventing the transition from coronary stability to instability and the occurrence of thrombosis events. Recently, multiple studies have suggested that the structure and composition of the gut microbiota in CAD patients exhibit significant alterations. According to a study conducted in Sweden [6], which involved 12 patients and 13 controls, the gut microbiota composition of patients with atherosclerosis (AS) contains relatively high levels of Collinsella, whereas that of the normal control group has relatively higher abundance of Roseburia and Eubacterium. Koren et al. identified Chryseomonas, Veillonella and Streptococcus in AS plaque samples, and several bacterial phylotypes from the gut are common to the atherosclerotic plaque and are correlated with the cholesterol levels [7]. A metagenome-wide association study showed that the abundance of Enterobacteriaceae and Streptococcus spp. were higher in patients with atherosclerotic cardiovascular disease than in healthy controls [8]. We hypothesize that the reason why discrepancies on microbial signatures of different atherosclerotic populations are due to the intrinsic flaw of taxon-based analysis, which overlooks the variations of the bacterial strains belonging to the same taxon. Moreover, the resident microbial communities in the intestinal tract act as key “metabolic filters” of the diet as these species can convert common nutrients to metabolites, and specific microbial-associated metabolites, such as trimethylamine-N-oxide (TMAO), short-chain fatty acids (SCFAs) and secondary bile acids, have been shown to affect the progression of CVD [9–13]. For example, TMAO, an independent marker for predicting clinical vascular events, has been mechanistically linked with the development of atherosclerosis in humans and mice. This substance is generated when a toxic metabolite (trimethylamine) produced by bacterial fermentation of dietary fat-derived choline enters the host bloodstream and is metabolized by the liver [14]. Both epidemiological and animal studies have provided strong evidence showing that alterations of the gut microbiota might be involved in the development of atherosclerosis, but the features of the gut microbiota in patients with different categories of CAD remain to be determined. To address the questions above, we analysed the gut microbial characteristics of 161 CAD patients (SCAD group N = 44, UA group N = 80, and MI group N = 37) and 40 healthy controls through high-throughput sequencing. In addition, we used untargeted liquid chromatography-mass spectrometry (LC-MS) to analyse the metabolic profiles of these patients. Based on these multi-omic analyses, we identified specific features of the gut microbiota and host metabolite profiles that are associated with increases in CAD severity and further established relationships, particularly between several bacterial co-abundance groups (CAGs) and serum metabolite function modules. This information may be used to construct a disease classifier for discriminating between healthy controls and different CAD subgroups (an overview of the workflow is provided in Additional file 1: Figure S1). Our study reveals that the integration of metabolomic and 16S rRNA V3-V4 sequencing analyses might reveal the interactions that occur between the host and the gut microbiome. RESULTS Characteristics of the study population A total of 201 participants were enrolled at Peking Union Medical College Hospital and were further divided into the following four groups based on guidelines for diagnosis (detailed in the “Materials and methods” section): control group (N = 40), SCAD group (N = 44), UA group (N = 80), and MI group (N = 37). The traditional cardiovascular risk factors of the 201 subjects are summarized in Table 1, and the extrinsic host factor profiles, including diet, lifestyle, and stool consistency, are summarized in Additional file 2: Table S1. Compared with the healthy subjects, the patients in the SCAD, UA and MI groups showed disruptions in glucose and lipid metabolism and an increased inflammatory state. Except for the significant differences in the hs-CRP levels between SCAD vs. MI and UA vs. MI, the risk factors showed no significant difference between comparisons of CAD subgroups. The atherosclerosis burden was quantified using the Gensini score [15], and the median scores of the